A targeted proteomics-based pipeline for verification of biomarkers in plasma

Nature Biotechnology

Volumn 29, Issue 7, 2011, Pages 625-634

  Whiteaker, Jeffrey R ^a   Lin, Chenwei ^a   Kennedy, Jacob ^a   Hou, Liming ^a   Trute, Mary ^a   Sokal, Izabela ^a   Yan, Ping ^a   Schoenherr, Regine M ^a   Zhao, Lei ^a   Voytovich, Uliana J ^a   Kelly Spratt, Karen S ^a   Krasnoselsky, Alexei ^a   Gafken, Philip R ^a   Hogan, Jason M ^a   Jones, Lisa A ^a   Wang, Pei ^a   Amon, Lynn ^a   Chodosh, Lewis A ^b   Nelson, Peter S ^a   McIntosh, Martin W ^a   Kemp, Christopher J ^a   Paulovich, Amanda G ^a   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL PERFORMANCE; BIOMARKER IDENTIFICATION; BREAST CANCER; CLINICAL STUDY; HIGH-THROUGHPUT TECHNOLOGIES; MOUSE MODELS; PLASMA SAMPLES; PRIORITIZATION; QUANTITATIVE ASSAY; SELECTED REACTION MONITORING;

DISEASES; MAMMALS; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MULTIPLEXING; PIPELINES; PLASMAS; PROTEINS;

BIOMARKERS;

BIOLOGICAL MARKER; PROTEIN;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PERFORMANCE; PLASMA; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SELECTED REACTION MONITORING MASS SPECTROMETRY;

ANIMALS; BLOOD CHEMICAL ANALYSIS; MASS SPECTROMETRY; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PEPTIDE MAPPING; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 79960214321     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1900     Document Type: Article

References (43)

1. Anderson, N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56, 177-185 (2010).
2. Anderson, N.L. et al. A human proteome detection and quantitation project. Mol. Cell. Proteomics 8, 883-886 (2009).
3. Bordeaux, J. et al. Antibody validation. Biotechniques 48, 197-209 (2010).
4. Haab, B.B. et al. A reagent resource to identify proteins and peptides of interest for the cancer community: a workshop report. Mol. Cell. Proteomics 5, 1996-2007 (2006). (Pubitemid 44688206)
5. Stoevesandt, O. & Taussig, M.J. Affinity reagent resources for human proteome detection: initiatives and perspectives. Proteomics 7, 2738-2750 (2007). (Pubitemid 47359918)
6. Jaffe, J.D. et al. Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol. Cell. Proteomics 7, 1952-1962 (2008).
7. Kuhn, E. et al. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4, 1175-1186 (2004). (Pubitemid 38445974)
8. Gerber, S.A., Rush, J., Stemman, O., Kirschner, M.W. & Gygi, S.P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 100, 6940-6945 (2003). (Pubitemid 36706372)
9. Barr, J. et al. Isotope-dilution mass spectrometric quantification of specific proteins: model application with apolipoprotein A-1. Clin. Chem. 42, 1676-1682 (1996). (Pubitemid 26354748)
10. Wu, S. et al. Targeted proteomics of low-level proteins in human plasma by LC/MSn: using human growth hormone as a model system. J. Proteome Res. 1, 459-465 (2002). (Pubitemid 36395865)
11. Barnidge, D., Goodmanson, M., Klee, G. & Muddiman, D. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution MS. J. Proteome Res. 3, 644-652 (2004). (Pubitemid 39207371)
12. Wang, P., Whiteaker, J.R. & Paulovich, A.G. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol. Ther. 8, 1083-1094 (2009).
13. Rifai, N., Gillette, M.A. & Carr, S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983 (2006). (Pubitemid 44215392)
14. Anderson, N.L. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol. Cell. Proteomics 4, 1441-1444 (2005). (Pubitemid 41555470)
15. Makawita, S. & Diamandis, E.P. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56, 212-222 (2010).
16. Lange, V., Picotti, P., Domon, B. & Aebersold, R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 4, 222 (2008).
17. Pan, S. et al. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 8, 787-797 (2009).
18. Carr, S.A. & Anderson, L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin. Chem. 54, 1749-1752 (2008).
19. Boja, E. et al. Restructuring proteomics through verification. Biomark Med 4, 799-803 (2010).
20. Paulovich, A.G., Whiteaker, J.R., Hoofnagle, A.N. & Wang, P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2, 1386-1402 (2008).
21. Whiteaker, J.R. et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 6, 3962-3975 (2007). (Pubitemid 350032560)
22. Schoenherr, R.M. et al. Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer. Proteomics Clin. Appl. 5, 179-188 (2011).
23. Moody, S.E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002). (Pubitemid 41043950)
24. Omenn, G.S., Yocum, A.K. & Menon, R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis. Markers 28, 241-251 (2010).
25. Zhang, H. et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol. Cell. Proteomics 10, M110.006593 (2011).
26. Anderson, N.L. et al. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J. Proteome Res. 3, 235-244 (2004). (Pubitemid 38500990)
27. Hoofnagle, A.N., Becker, J.O., Wener, M.H. & Heinecke, J.W. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 54, 1796-1804 (2008).
28. Kuhn, E. et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 55, 1108-1117 (2009).
29. Whiteaker, J.R., Zhao, L., Anderson, L. & Paulovich, A.G. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 9, 184-196 (2010).
30. Want, E.J., Cravatt, B.F. & Siuzdak, G. The expanding role of mass spectrometry in metabolite profiling and characterization. ChemBioChem 6, 1941-1951 (2005). (Pubitemid 41598162)
31. Picotti, P. et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat. Methods 7, 43-46 (2010).
32. Kiyonami, R. et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol. Cell. Proteomics 10, M110.002931 (2011).
33. Whiteaker, J.R. et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 10, M110.005645 (2011).
34. Fraser, C.G. Biological Variation: from Principles to Practice (AACC Press, Washington, DC; 2001).
35. Hoofnagle, A.N. & Wener, M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347, 3-11 (2009).
36. Keshishian, H. et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 8, 2339-2349 (2009).
37. Stahl-Zeng, J. et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6, 1809-1817 (2007). (Pubitemid 350031682)
38. Keshishian, H., Addona, T., Burgess, M., Kuhn, E. & Carr, S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229 (2007).
39. Anderson, L. & Hunter, C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588 (2006).
40. Ekins, R. & Edwards, P. On the meaning of "sensitivity". Clin. Chem. 43, 1824-1831 (1997).
41. Ekins, R. & Edwards, P. On the meaning of "sensitivity": a rejoinder. Clin. Chem. 44, 1773-1778 (1998).
42. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966-968 (2010).
43. Schoenherr, R.M. et al. Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography- selected reaction monitoring-mass spectrometry. J. Immunol. Methods 353, 49-61 (2010).